Melfalan Hikma

Melphalan, the active ingredient in Melfalan Hikma, is an alkylating agent presented as an intravenous solution for intravenous use. It is employed in the treatment of multiple myeloma, ovarian cancer, malignant melanoma and chronic lymphocytic leukemia, primarily in adult patients requiring systemic chemotherapy.

GNH USA supplies Melfalan Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, providing reliable access to EU‑sourced chemotherapy agents. The company adheres to stringent quality standards and offers comprehensive logistics support for global distribution.

Melphalan is an alkylating chemotherapy agent used in the management of several hematologic and solid tumor malignancies. - Multiple myeloma: reduces malignant plasma cells and prolongs survival. - Ovarian cancer: used in combination regimens to achieve tumor reduction. - Malignant melanoma: employed as part of high‑dose therapy for metastatic disease. - Chronic lymphocytic leukemia: contributes to disease control in refractory cases.

Melphalan may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset commonly reported. - Fatigue: persistent tiredness during therapy. - Myelosuppression: reduced blood cell counts causing anemia, neutropenia or thrombocytopenia.

Serious or Rare Side Effects: - Secondary malignancies: risk of therapy‑related cancers. - Severe infection: due to profound neutropenia. - Pulmonary toxicity: interstitial pneumonitis or fibrosis.

When using melphalan, several precautions should be observed to minimize risks and ensure safe handling. - Monitor blood counts: regular CBC testing to detect myelosuppression. - Assess renal function: evaluate creatinine clearance before and during therapy. - Use anti‑emetics: prophylactic medication to control nausea and vomiting. - Avoid in pregnancy: melphalan is contraindicated in pregnant patients due to fetal toxicity. - Protective handling: healthcare personnel should wear gloves and use closed system transfer devices. - Store at ambient temperature: keep the solution below 25°C, protected from light, and in the original container.

Melphalan can interact with other medicines, altering its efficacy or toxicity.

Major Interactions (Avoid): - Live vaccines: may cause severe infection due to immunosuppression. - CYP450 inducers: drugs such as rifampin can reduce melphalan plasma levels. - High‑dose radiotherapy: combined use increases risk of severe tissue damage.

Moderate Interactions (Monitor Closely): - Antifungals (azoles): may increase melphalan toxicity. - Allopurinol: can enhance myelosuppression. - NSAIDs: may exacerbate renal toxicity.